REVIEW ARTICLE
Year : 2019 | Volume
: 14 | Issue : 3 | Page : 165--172
Biomarkers and clinical scoring systems in community-acquired pneumonia
Meropi Karakioulaki1, Daiana Stolz2
1 Department of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
2 Department of Pulmonary Medicine and Respiratory Cell Research, University Hospital Basel, Basel, Switzerland
Correspondence Address:
Prof. Daiana Stolz
Clinic of Pulmonary Medicine and Respiratory Cell Research, University Hospital Basel, Petersgraben 4, CH-4031 Basel
Switzerland
Community-acquired pneumonia (CAP) is the third most common cause of death globally. Due to the complexity of CAP, it is widely accepted that, currently, clinical prognosis and diagnosis is inadequate for the assessment of the severity of the disease. With the aim to determining the initial treatment and the appropriate level of intervention, several clinical scores of severity and biomarkers have been developed. Both biomarkers and clinical scoring systems are expected to determine the different aspects of the host factor and the response to therapy, in order for physicians to be able to make an accurate benefit/risk assessment that will lead to proper diagnosis and correct prescription of antibiotics. This review aims to highlight the prognostic and diagnostic accuracy of various laboratory and clinical parameters in CAP and discuss the perspectives for the reduction of CAP mortality.
How to cite this article:
Karakioulaki M, Stolz D. Biomarkers and clinical scoring systems in community-acquired pneumonia.Ann Thorac Med 2019;14:165-172
|
How to cite this URL:
Karakioulaki M, Stolz D. Biomarkers and clinical scoring systems in community-acquired pneumonia. Ann Thorac Med [serial online] 2019 [cited 2023 Apr 2 ];14:165-172
Available from: https://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2019;volume=14;issue=3;spage=165;epage=172;aulast=Karakioulaki;type=0 |
|
|
|
